1610758-22-9 Usage
Uses
Used in Pharmaceutical Industry:
Dabigatran iMpurity D is used as a critical component in the development and quality control of Dabigatran Ethyl Ester. It is essential for assessing the purity and safety of the final drug product, ensuring that the therapeutic benefits of Dabigatran are not compromised by the presence of impurities.
Used in Research and Development:
Dabigatran iMpurity D serves as an important reference material for researchers and scientists working on the development of new antithrombotic agents or improving the existing ones. It helps in understanding the structure-activity relationship and potential side effects associated with Dabigatran, leading to the design of safer and more effective drugs.
Used in Quality Control and Regulatory Compliance:
Dabigatran iMpurity D is used as a reference standard in the quality control processes of pharmaceutical manufacturers. It helps in the identification, quantification, and control of impurities in the final drug product, ensuring compliance with regulatory guidelines and maintaining the overall quality of Dabigatran Ethyl Ester.
Check Digit Verification of cas no
The CAS Registry Mumber 1610758-22-9 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,6,1,0,7,5 and 8 respectively; the second part has 2 digits, 2 and 2 respectively.
Calculate Digit Verification of CAS Registry Number 1610758-22:
(9*1)+(8*6)+(7*1)+(6*0)+(5*7)+(4*5)+(3*8)+(2*2)+(1*2)=149
149 % 10 = 9
So 1610758-22-9 is a valid CAS Registry Number.
1610758-22-9Relevant academic research and scientific papers
Identification, synthesis, and strategy for the reduction of potential impurities observed in dabigatran etexilate mesylate processes
Zheng, Yong-Yong,Shen, Cheng-Wu,Zhu, Mei-Yu,Zhou, Yi-Meng,Li, Jian-Qi
, p. 744 - 750 (2014/07/08)
Synthetic impurities that are present in dabigatran etexilate mesylate were studied, and possible pathways by which these impurities are formed during the manufacturing process were examined. The impurities were monitored by high-performance liquid chromatography, and their structures were determined by mass spectrometry and 1H and 13C NMR. Potential causes for the formation of these impurities are discussed, and strategies to minimize their formation are also described.
